ArticleFrontiers in cardiovascular medicine2025
Target vessel-specific efficacy and short-term outcomes of rotational atherectomy in the treatment of chronic total occlusion.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To compare the procedural features, treatment efficacy, and short-term outcomes of RA for CTO in different target vessels-LAD, LCX, and RCA-and to assess the anatomical compatibility and clinical benefit of RA. Methods: This retrospective study included 119 patients with single-vessel CTO who underwent RA-assisted PCI from January 2019 to December 2024. Patients were divided into LAD ( Results: RCA-CTO patients were older and had more triple-vessel disease, but showed the lowest MACCEs rate at 6 months (10.0%) compared with LAD (23.6%) and LCX (28.6%) ( Conclusion: RA-assisted PCI is safe and feasible for heavily calcified CTO lesions. Observed outcomes showed some variation by target vessel, with RCA-CTO appearing to have relatively better short-term results. Intravascular imaging may be helpful for guidance, but in this cohort it was not associated with a statistically significant reduction in 6-month MACCEs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.